BENLYSTA, generically known as belimumab, is a prescription medication specifically designed to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease where the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. It belongs to a class of drugs known as monoclonal antibodies, which target and inhibit the activity of B-lymphocyte stimulator (BLyS) protein. By blocking BLyS, BENLYSTA reduces the survival of B cells, including autoreactive B cells that produce antibodies against the body's own tissues, thereby helping to decrease the inflammation and autoantibody production associated with lupus. BENLYSTA is administered through intravenous infusion or as a subcutaneous injection and is used in adults and children who meet specific clinical criteria, offering a targeted approach to managing the symptoms of this complex and variable condition.
When using BENLYSTA, it is crucial to take certain precautions to ensure your safety and the effectiveness of the treatment. Firstly, always follow your doctor's instructions precisely and read the medication label carefully for dosing and other important information. BENLYSTA can cause side effects that may impair your ability to drive or operate machinery safely. Common side effects include nausea, diarrhea, fever, and infections, while rare but serious side effects can include severe allergic reactions and depression. It is essential to report any unusual symptoms to your doctor immediately. Additionally, inform your doctor about all other medications you are taking, as BENLYSTA can interact with other drugs, potentially leading to adverse effects. Adhering to these guidelines will help minimize risks and maximize the benefits of your treatment.